Avidity Biosciences — Investor Day (November 2024)
38 slides from Avidity Biosciences's investor day presentation, Nov 12, 2024
Slide 1: Precision Cardiology: Transforming Genetic Cardiomyopathy Treatment & First Look at Next-Generation Innovations
1 Investor & Analyst Event Series – Volume 11 Precision Cardiology: Transforming Genetic Cardiomyopathy Treatment & First Look at Next-Generation Innovations November 12, 2024 NASDAQ: RNA | aviditybio.com
Slide 2: Forward-looking statements
2 We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include, but are not
Slide 3: Our Vision
3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics
Slide 4: Goals of the Day
4 Goals of the Day Provide a first look at innovations in our next-generation technology Present preclinical data from our first two wholly-owned precision cardiology programs Share our precision cardiology strategy – utilizing our AOC technology to target the root cause of genetic cardiac diseases
Slide 5: Beyond Our Late-Stage Clinical Pipeline: Transforming Cardiac Care
5 Beyond Our Late-Stage Clinical Pipeline: Transforming Cardiac Care First two, wholly-owned precision cardiology candidates targeting rare genetic cardiomyopathies with high unmet needs • AOC 1086 to treat PLN Cardiomyopathy (Phospholamban) • AOC 1072 to treat PRKAG2 Syndrome (Protein Kinase AMP-ac
Slide 6: Avidity Management Team
6 Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO W. Michael Flanagan, Ph.D. Chief Scientific & Technical Officer Precision Cardiology: Transforming Heart Disease Treatment AVIDITY MANAGEMENT TEAM Michael MacLean Chief Financial & Business Officer Georgios Karamanlidis, Ph.D. Ca
Slide 7: Agenda/Outline
7 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Precision Cardiology: Transforming Treatment of Cardiomyopathies Michael Flanagan, Ph.D., CSO & CTO Targeting PLN Cardiomyopathy Georgios Karamanlidis, Ph.D. Cardiology Team Leader Targeting PRKAG2 Syndrome Next-genera
Slide 8: The Perfect Pair: Our AOC Technology and Precision Cardiology
8 The Perfect Pair: Our AOC Technology and Precision Cardiology HEART DISEASE is #1 cause of death globally* PRECISION CARDIOLOGY targets an underlying disease-causing genetic mutation in the heart muscle *World Health Organization TARGETED siRNA DELIVERY TO CARDIAC MUSCLE GENETIC MUTATIONS IN THE H
Slide 9: Cardiomyopathies: Serious Life-threatening Condition
9 Dilated Cardiomyopathy (DCM) Arrhythmogenic Cardiomyopathy (ACM) Hypertrophic Cardiomyopathy (HCM) Cardiomyopathies: Serious Life-threatening Condition that Impacts People in The Prime of Their Life ACMDCM HCM occurs when the left ventricle is abnormally thick and stiff, leading to reduced ability
Slide 10: AOC Technology Uniquely Positioned for Precision Cardiology Therapeutics
10 AOC Technology Uniquely Positioned for Development of Precision Cardiology Therapeutics Targeted siRNA Delivery to the Heart Platform Safety and Tolerability Target the Genetic Cause of Disease Line of Sight to the Clinic • Best in Class siRNA - potent and durable siRNA • siRNA delivery to cardio
Slide 11: Georgios Karamanlidis, Ph.D., Cardiology Team Leader
11 Georgios Karamanlidis, Ph.D. Cardiology Team Leader Georgios Karamanlidis, Ph.D., joined Avidity Biosciences in 2021 and serves as the Cardiology Team Leader within research. With over a decade of drug discovery and development experience, including work on small molecules, antibodies, and antibo
Slide 12: Agenda/Outline
12 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Precision Cardiology: Transforming Treatment of Cardiomyopathies Michael Flanagan, Ph.D., CSO & CTO Targeting PLN Cardiomyopathy Georgios Karamanlidis, Ph.D. Cardiology Team Leader Targeting PRKAG2 Syndrome Next-gener
Slide 13: Precision Cardiology Development Candidates Targeting PLN and PRKAG2
13 Precision Cardiology Development Candidates Targeting PLN and PRKAG2 Advancing new class of targeted RNA therapeutics to address rare genetic cardiomyopathies AOC 1086 PLN Cardiomyopathy (Phospholamban) AOC 1072 PRKAG2 Syndrome (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Robust s
Slide 14: PLN Cardiomyopathy: Hereditary Disease Resulting in Dilated and Arrhythmogenic Cardiomyopathy
14 0 APPROVED DISEASE- MODIFYING THERAPIES PLN Cardiomyopathy: Hereditary Disease Resulting in Dilated and Arrhythmogenic Cardiomyopathy ~2,000-4,000 PEOPLE LIVING WITH PLN CARDIOMYOPATHY (US and CANADA) • Autosomal dominant, progressive cardiac disease characterized by dilated and/or arrhythmogenic
Slide 15: AOC 1086 Targets and Degrades PLN mRNA
15 AOC 1086 Targets and Degrades PLN mRNA to Eliminate Protein Aggregates in PLN Cardiomyopathy PLN CARDIOMYOPATHY MECHANISM OF DISEASE PLN-R14del MUTATION PLN-R14del PROTEIN AGGREGATES HEART DISEASE CAUSED BY ABNORMAL CELL FUNCTION AND DEATH
Slide 16: AOC 1086 Targets and Degrades PLN mRNA
16 AOC 1086 Targets and Degrades PLN mRNA to Eliminate Protein Aggregates in PLN Cardiomyopathy PLN CARDIOMYOPATHY MECHANISM OF DISEASE AOC 1086 THERAPEUTIC HYPOTHESIS PLN-R14del MUTATION PLN-R14del PROTEIN AGGREGATES HEART DISEASE CAUSED BY ABNORMAL CELL FUNCTION AND DEATH siRNA DELIVERY TO CARDIAC
Slide 17: AOC 1086 Demonstrates Robust siRNA Cardiac Delivery in NHP
17 Single dose of AOC 1086 at 3mg/kg (of siRNA) with evaluation 28 days post-dose DELIVERY TARGET ENGAGEMENT TOLERABILITY AOC 1086 Demonstrates Robust siRNA Cardiac Delivery in Non-Human Primates (NHP) AOC 1086 1 10 100 siRNA concentration in NHP heart nM Mean +SD, n=2 siRNA concentration in NHP hea
Slide 18: AOC 1086 Demonstrates Target Knockdown in Cardiac PLN mRNA and Protein
18 AOC 1086 Demonstrates Target Knockdown with Potent Reduction in Cardiac PLN mRNA and Protein in NHP Single dose of AOC 1086 at 3mg/kg (of siRNA) with evaluation 28 days post-dose Target protein reduction in NHP heart PLN Pentamer PLN Monomer Control AOC 1086Control AOC 1086 0 25 50 75 100 125 Tar
Slide 19: AOC 1086 Well-Tolerated With No Effect on ECG Parameters in NHP
19 AOC 1086 PLN Inhibition Well-Tolerated With No Effect on Electrocardiogram (ECG) Parameters in NHP Single dose of AOC 1086 at 3mg/kg (of siRNA) with evaluation 28 days post-dose Tolerability No effect on ECG parameters for evaluating cardiac changes DELIVERY TARGET ENGAGEMENT TOLERABILITY Control
Slide 20: PRKAG2 Syndrome: Hereditary Disease Causing Hypertrophic Cardiomyopathy
20 PRKAG2 Syndrome: Hereditary Disease Causing Hypertrophic Cardiomyopathy and Wolff-Parkinson-White Syndrome ~1,000-2,000 PEOPLE LIVING WITH PRKAG2 SYNDROME (US and CANADA) • Autosomal dominant, progressive cardiac disease characterized by hypertrophic cardiomyopathy, arrhythmia and heart failure •
Slide 21: AOC 1072 Targets and Degrades PRKAG2 mRNA
21 AOC 1072 Targets and Degrades PRKAG2 mRNA to Reduce Glycogen Accumulation in PRKAG2 Syndrome PRKAG2 SYNDROME MECHANISM OF DISEASE PRKAG2 MUTATION HIGH AMPK ACTIVITY INCREASE CARDIAC GLYCOGEN STORAGE LEADING TO HEART DISEASE
Slide 22: AOC 1072 Targets and Degrades PRKAG2 mRNA
22 AOC 1072 Targets and Degrades PRKAG2 mRNA to Reduce Glycogen Accumulation in PRKAG2 Syndrome PRKAG2 SYNDROME MECHANISM OF DISEASE AOC 1072 THERAPEUTIC HYPOTHESIS PRKAG2 MUTATION HIGH AMPK ACTIVITY INCREASE CARDIAC GLYCOGEN STORAGE LEADING TO HEART DISEASE TARGETED SiRNA DELIVERY TO CARDIAC MUSCLE
Slide 23: AOC 1072 Demonstrates Robust siRNA Cardiac Delivery in NHP
23 AOC 1072 Demonstrates Robust siRNA Cardiac Delivery in NHP Single dose of AOC 1072 at 3mg/kg (of siRNA) with evaluation 28 days post-dose AOC 1072 1 10 100 siRNA concentration in NHP heart nM DELIVERY TARGET ENGAGEMENT TOLERABILITY siRNA concentration in NHP heart (nM) Mean +SD, n=3
Slide 24: AOC 1072 Demonstrates Target Knockdown in Cardiac PRKAG2 mRNA and Protein
24 Single dose of AOC 1072 at 3mg/kg (of siRNA) with evaluation 28 days post-dose AOC 1072 Demonstrates Target Knockdown with Potent Reduction in Cardiac PRKAG2 mRNA and Protein in NHP Mean +SD, n=2 for the control group and n=3 for the AOC 1072 group Target protein reduction in NHP heart DELIVERY T
Slide 25: AOC 1072 PRKAG2 Inhibition Well-Tolerated With No Effect on ECG
25 Single dose of AOC 1072 at 3mg/kg (of siRNA) with evaluation 28 days post-dose AOC 1072 PRKAG2 Inhibition Well-Tolerated With No Effect on Electrocardiogram (ECG) Parameters in NHP n=2 for the control group and n=3 for the AOC 1072 group DELIVERY TARGET ENGAGEMENT TOLERABILITY Control AOC 1072 0
Slide 26: Precision Cardiology Development Candidates Targeting PLN and PRKAG2
26 Precision Cardiology Development Candidates Targeting PLN and PRKAG2 Advancing new class of targeted RNA therapeutics to address genetic cardiomyopathies AOC 1086 PLN Cardiomyopathy (Phospholamban) AOC 1072 PRKAG2 Syndrome (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Robust siRNA
Slide 27: Agenda/Outline
27 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Precision Cardiology: Transforming Treatment of Cardiomyopathies Michael Flanagan, Ph.D., CSO & CTO Targeting PLN Cardiomyopathy Georgios Karamanlidis, Ph.D. Cardiology Team Leader Targeting PRKAG2 Syndrome Next-gener
Slide 28: Innovation Drives Our Industry-leading RNA Platform Technology
28 Innovation Drives Our Industry-leading RNA Platform Technology Leading RNA Delivery Technology Innovations Improved delivery Patient convenience Increased durability ANTIBODY siRNA Delivery ligands siRNA Modifications PeptideAb Lipids
Slide 29: First Look into Next-Gen AOC Innovations: siRNA Modification and Antibody Engineering
29 First Look into Next-Gen AOC Innovations: siRNA Modification and Antibody Engineering AOC mAb OLIGO In the Clinic Today Tomorrow Future siRNA Modification siRNA Modification & Antibody Engineering Indicates modifications
Slide 30: Next-Gen siRNA Modifications Provide Greater Than 4-Fold Increase in Delivery to Muscle in Mice
30 Next-Gen siRNA Modifications Provide Greater Than 4-Fold Increase in Delivery to Muscle in Mice Improved Delivery AOC Next Gen 0 2 4 6 si R N A Ti ss ue C on ce nt ra tio n Fo ld In cr ea se siRNA Modification Indicates modifications Single dose of 0.75 mg/kg siRNA equivalent; Day 28; n = 4
Slide 31: Next-Gen siRNA Modifications Show Sustained Target Inhibition for 3 Months in Mice
31 Next-Gen siRNA Modifications Show Sustained Target Inhibition for 3 Months in Mice; Potential for Convenient Less Frequent Dosing Increased Durability Improved Patient Convenience siRNA Modification Indicates modifications Single dose of 0.75 mg/kg of siRNA equivalent; n = 4
Slide 32: siRNA and Antibody Innovations Lead to >30-Fold Increase in Delivery to Skeletal Muscle
32 siRNA and Antibody Innovations Lead to >30-Fold Increase in siRNA Delivery to Skeletal Muscle in Non-Human Primates (NHP) Single dose of 1.0 mg/kg siRNA equivalent; Day 29, n = 3 Improved DeliverysiRNA Modification & Antibody Engineering Indicates modifications
Slide 33: Unlocking New Levels of Delivery and Durability with Next-Gen Innovations
33 Unlocking New Levels of Delivery and Durability with Next-Gen Innovations Patient convenience Increased durability Next-Generation Technology Innovations • >30-fold increase in siRNA delivery to skeletal muscle in non-human primates • Potential for less frequent dosing and patient convenient subQ
Slide 34: Agenda/Outline
34 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Precision Cardiology: Transforming Treatment of Cardiomyopathies Michael Flanagan, Ph.D., CSO & CTO Targeting PLN Cardiomyopathy Georgios Karamanlidis, Ph.D. Cardiology Team Leader Targeting PRKAG2 Syndrome Next-gener
Slide 35: Delivering on the RNA Revolution
35 Delivering on the RNA Revolution PROGRAM / INDICATION TARGET PRE-IND PHASE 1/2 PHASE 3 Myotonic Dystrophy Type 1 (DM1) DMPK Facioscapulohumeral Muscular Dystrophy (FSHD) DUX4 Duchenne Muscular Dystrophy (DMD) Exon 44 DMD Exon 45 Exon 45 Additional DMD Programs Undisclosed Rare Skeletal Muscle Und
Slide 36: Our Vision
36 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics
Slide 37: Q&A
37 Investor & Analyst Event Series – Volume 11 Precision Cardiology: Transforming Genetic Cardiomyopathy Treatment & First Look at Next-Generation Innovations Q&A November 12, 2024 NASDAQ: RNA | aviditybio.com
Slide 38: Precision Cardiology: Transforming Genetic Cardiomyopathy Treatment & First Look at Next-Generation Innovations
38 Investor & Analyst Event Series – Volume 11 Precision Cardiology: Transforming Genetic Cardiomyopathy Treatment & First Look at Next-Generation Innovations November 12, 2024 NASDAQ: RNA | aviditybio.com